Popular Trials
Monoclonal Antibodies
PRA023 for Crohn's Disease
This trial is testing a new medication called PRA023 for people with moderately to severely active Crohn's Disease. The medication aims to reduce inflammation in the digestive tract, which should help relieve symptoms like pain and diarrhea. Participants will initially take the medication for a few months and may choose to continue for several more months.
Monoclonal Antibodies
Infliximab Optimization for Crohn's Disease
This trial tests if using a computer program to decide infliximab doses is better and safer than standard dosing for patients with inflammatory bowel disease. The program helps doctors choose the best dose by looking at individual health details, aiming to keep the medication working well and prevent the disease from getting worse. Infliximab is commonly used to treat inflammatory bowel disease, and dose optimization has been shown to improve treatment outcomes.
Amino Acid
Dietary Intakes for Crohn's Disease
This trial is testing the hypothesis that the threonine requirements of patients with Crohn's disease are higher than previously determined in healthy adults, using the IAAO method. Up to 10 patients will be followed over 3 days, during which they will consume a prescribed diet and have their Phe kinetics measured.
Popular Filters
Trials for Inflammatory Bowel Disease Patients
Cannabinoid
Medical Cannabis for Chronic Pain
This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
2'-FL Supplement for Inflammatory Bowel Disease
This trial tests 2'-FL, a sugar from breast milk, as a dietary supplement for young IBD patients in stable remission. It aims to boost good gut bacteria and improve gut health by increasing butyrate levels. 2'-FL, a human milk oligosaccharide, has been shown to promote the growth of beneficial gut bacteria and improve gut health in various studies.
Trials for IBD Patients
Cannabinoid
Medical Cannabis for Chronic Pain
This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
2'-FL Supplement for Inflammatory Bowel Disease
This trial tests 2'-FL, a sugar from breast milk, as a dietary supplement for young IBD patients in stable remission. It aims to boost good gut bacteria and improve gut health by increasing butyrate levels. 2'-FL, a human milk oligosaccharide, has been shown to promote the growth of beneficial gut bacteria and improve gut health in various studies.
Phase 3 Trials
Monoclonal Antibodies
Ustekinumab for Pediatric Crohn's Disease
This trial is testing a medication that reduces inflammation in children with severe Crohn's disease. The goal is to see if it can help them get better and stay better. The study will also check how safe the medication is and how it works in the body.
Monoclonal Antibodies
Guselkumab for Crohn's Disease
This trial is testing guselkumab, a medication that reduces inflammation, in patients with moderate to severe Crohn's disease. It works by blocking a protein called IL-23, which helps to lower inflammation in the body. Guselkumab is a monoclonal antibody that selectively inhibits IL-23 and has shown efficacy in treating inflammatory conditions like psoriasis and Crohn's disease.
Monoclonal Antibodies
Guselkumab for Crohn's Disease
This trial is testing guselkumab, a medication that reduces inflammation, in patients with Crohn's disease. It aims to find the best dose and check its safety and effectiveness. The medication works by calming the immune system to reduce symptoms.
Trials With No Placebo
Cannabinoid
Medical Cannabis for Chronic Pain
This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
View More Related Trials
Frequently Asked Questions
Introduction to crohn's disease
What are the top hospitals conducting crohn's disease research?
When it comes to advancing the treatment options for individuals with Crohn's disease, several hospitals are leading the charge. Boston Children's Hospital in Boston is at the forefront of research and innovation, currently conducting eight active clinical trials for this condition. Since their first recorded trial in 2015, they have completed a total of 15 trials dedicated to understanding and improving outcomes for those living with Crohn's disease.
Moving south to Clearwater, Florida, Gastro Florida is also making significant strides in Crohn's disease research. With seven ongoing trials and a history of 14 previous studies since their initial trial in 2017, this hospital is actively contributing to the body of knowledge surrounding this chronic inflammatory bowel disorder.
In Nashville, Tennessee, Vanderbilt University Medical Center has established itself as a prominent institution when it comes to studying Crohn's disease. Currently engaged in seven active clinical trials and having conducted an impressive total of 46 trials since their inaugural investigation in 2004.
Indiana University located in Indianapolis plays its part too; engaging six active crohn’s diseases investigations while having expertise stemming from fifteentrials through starting early work on tackling such cases back towards2007
Yale University based out New Haven might be smaller-scale but still holds valuable contributions by carrying out six contemporary tests whilst maintaining record building nineinvestigations only dating back until 2014.
These hospitals represent beacons of hope for individuals affected by Crohn's disease worldwide. By investing significant resources into clinical trials focused on enhancing our understanding and treatment options for this complex condition these institutions play crucial roles aidingin shaping better future outlooks not just locally but globally
Which are the best cities for crohn's disease clinical trials?
When it comes to crohn's disease clinical trials, several cities emerge as top contenders for cutting-edge research. New york leads the way with 49 active trials focusing on promising treatments like Ozanimod, Risankizumab SC, and PF-06651600. Miami follows closely behind with 37 ongoing studies investigating potential breakthroughs such as Ozanimod, Mirikizumab, and Etrasimod. Atlanta also stands out with 33 active trials exploring treatment options like Ozanimod, Mirikizumab, and Ustekinumab. Additionally, Chicago and Orlando showcase their commitment to advancing crohn's disease care through their respective 27 and 26 active trials that delve into promising interventions including Ozanimod, Upadacitinib, Mirikizumab, Guselkumab Dose 3. These cities offer individuals living with crohn's disease opportunities to participate in groundbreaking clinical trials that hold promise for improved management of the condition.
Which are the top treatments for crohn's disease being explored in clinical trials?
Crohn's disease, a challenging condition to manage, has seen promising advancements in recent clinical trials. Leading the pack is ozanimod, currently being explored in five active trials dedicated to this chronic inflammatory disorder since its introduction in 2018. Close behind is ustekinumab with three ongoing studies and an impressive track record of 27 all-time crohn's disease trials since 2013. Also vying for attention is mirikizumab which shares similar stats as ustekinumab—three active trials and five all-time crohn's disease trials starting from 2016. Lastly, resistant starch joins the race with two active and two all-time crohn's disease trials listed from 2020 onwards. These cutting-edge treatments offer hope for improved management and quality of life for patients grappling with Crohn’s disease.
What are the most recent clinical trials for crohn's disease?
Recent clinical trials have brought new hope to individuals living with Crohn's disease, a challenging condition that affects the digestive system. One groundbreaking study focuses on guselkumab IV, an open-label induction phase treatment for Crohn's disease that has entered Phase 3 of testing, becoming available for participants from September 21, 2023. Another promising trial involves ozanimod and its potential application in managing Crohn's disease; it has reached Phases 2 and 3 as of August 22, 2023. Additionally, there is ongoing research into the effectiveness of anti-IL12/23 or anti-IL23 medications in treating Crohn's disease during its Phase 4 stage since August1st, 2023. These advancements bring optimism to patients seeking better outcomes through cutting-edge therapies tailored specifically for their needs.
What crohn's disease clinical trials were recently completed?
Recently completed clinical trials for Crohn's disease have shown promising advancements in the field. Stanford University successfully concluded a trial investigating the use of Vitamin d in July 2021, while UCB Biopharma SRL wrapped up their study on certolizumab pegol pharmacokinetics in June 2020. AbbVie also reached a significant milestone with their Risankizumab trial in May 2020. These trials, along with others conducted by Reistone Biopharma Company Limited, Genentech Inc., Janssen-Cilag Ltd., and other reputable sponsors, contribute to our understanding of potential treatments for Crohn's disease and offer hope to patients navigating this challenging condition.